Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KY 0301

Next Previous
Drug Profile

KY 0301

Alternative Names: KY-0301

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novatim Immune Therapeutics (Zhejiang)
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
  • Mechanism of Action Epidermal growth factor modulators; Proto-oncogene protein c-met modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Apr 2025 Novatim Immune Therapeutics plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) (IV), in May 2025 (NCT06928363)
  • 13 Sep 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 08 Apr 2024 Preclinical trials in Solid tumours in USA and China (Parenteral) (Novatim Immune Therapeutics pipeline, April 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top